PriceTargets.com logo

Precipio - PRPO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $2.85
  • Forecasted Upside: 378.99%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.60 As of 03/22/2023 03:34 PM ET
▼ -0.03 (-4.80%)

This chart shows the closing price for PRPO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Precipio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRPO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRPO

Analyst Price Target is $2.85
▲ +378.99% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Precipio in the last 3 months. The average price target is $2.85, with a high forecast of $2.85 and a low forecast of $2.85. The average price target represents a 378.99% upside from the last price of $0.60.

This chart shows the closing price for PRPO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Precipio. This rating has held steady since March 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/3/2023Alliance Global PartnersLower Target$6.30 ➝ $2.85Low
4/1/2021Maxim GroupBoost TargetBuy$2.00 ➝ $7.00High
5/21/2020Maxim GroupReiterated RatingBuy$2.00High
11/22/2019Maxim GroupInitiated CoverageBuy$4.00Low
(Data available from 3/22/2018 forward)

News Sentiment Rating

-0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
8/24/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/22/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Precipio logo
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
Read More

Today's Range

Now: $0.60
Low: $0.60
High: $0.66

50 Day Range

MA: $0.80
Low: $0.60
High: $1.00

52 Week Range

Now: $0.60
Low: $0.47
High: $1.77

Volume

34,798 shs

Average Volume

91,915 shs

Market Capitalization

$13.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Precipio?

The following equities research analysts have issued reports on Precipio in the last twelve months: Alliance Global Partners.
View the latest analyst ratings for PRPO.

What is the current price target for Precipio?

1 Wall Street analysts have set twelve-month price targets for Precipio in the last year. Their average twelve-month price target is $2.85, suggesting a possible upside of 356.0%. Alliance Global Partners has the highest price target set, predicting PRPO will reach $2.85 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $2.85 for Precipio in the next year.
View the latest price targets for PRPO.

What is the current consensus analyst rating for Precipio?

Precipio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PRPO.

What other companies compete with Precipio?

Other companies that are similar to Precipio include Talis Biomedical, SeqLL, IsoPlexis, Rapid Micro Biosystems and Accelerate Diagnostics. Learn More about companies similar to Precipio.

How do I contact Precipio's investor relations team?

Precipio's physical mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company's listed phone number is (203) 787-7888 and its investor relations email address is [email protected] The official website for Precipio is www.precipiodx.com. Learn More about contacing Precipio investor relations.